Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2018 call → NO我们根据提供的财报电话会议记录来判断管理层是否描述了公司同类业务连续承接的规模在逐步扩大。需要寻找管理层关于交易、订单、合同、项目、客户、网站或项目规模与过去相比增大的表述。 在记录中,Andy提到了一些亮点,比如“recurring dollar retention rate was 103% a multi-year high point”,以及“strong bookings performance across both business groups and across all geographies”。但这是关于整体预订和保留率,不是关于单个交易规模。 关于大型交易,Andy提到“a three-year multi-million dollar transaction with one of the world's largest auto companies”,并说“This existing customer had previously used Brightcove in one segment of its business and was looking to standardize on a single platform for its internal communications.” 这描述了一个现有客户扩大使用范围,但这是否表明“同类业务连续承接的规模在逐步扩大”?这更像是一个客户扩展,而不是新交易规模普遍增大。 管理层没有明确说“新订单的平均规模比过去大”或“新客户一开始就比老客户大”等。他们提到“we saw good early results from the changes we have made in our North American media sales team”和“Europe had the best quarter we have seen in that region in several years”,但这些都是关于区域表现,不是关于交易规模。 关于“recurring dollar retention rate”达到103%,这反映了upsell,但upsell可能意味着现有客户增加支出,但这不是新交易规模增大,而是现有客户扩展。 管理层没有提到“largest deal in company history”或“deals are getting bigger”之类的表述。他们提到一个大型交易,但将其作为“a great example of the land and expand opportunity”,而不是作为规模上升趋势的一部分。 因此,没有证据表明管理层描述了同类业务连续承接的规模在逐步扩大。回答应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.